Cost-effectiveness of age-based and risk-based use of the new 21-valent pneumococcal conjugate vaccine among U.S. adults. Stoecker C, Wang Y, Leidner AJ, Cho BH, et al. Vaccine 2025;69:127940.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Stoecker C, Wang Y, Leidner AJ, Cho BH, et al. Cost-effectiveness of age-based and risk-based use of the new 21-valent pneumococcal conjugate vaccine among U.S. adults. Vaccine 2025;69:127940.
PMID: 41274026